Fennec Pharmaceuticals Inc. (FENC) financial statements (2020 and earlier)

Company profile

Business Address PO BOX 13628
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. BC
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1423284122
Cash and cash equivalents1423284122
Prepaid expense0000000
Other current assets0000000
Total current assets:1423284122
Noncurrent Assets
Other undisclosed noncurrent assets0      
Total noncurrent assets:0      
TOTAL ASSETS:1423284122
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2210000
Accounts payable2110000
Accrued liabilities1110000
Derivative instruments and hedges, liabilities  00013
Total current liabilities:2220023
Noncurrent Liabilities
Total liabilities:2220023
Stockholders' equity
Stockholders' equity attributable to parent, including:122127411(1)
Common stock10610610375696967
Additional paid in capital48454442424239
Accumulated other comprehensive income1111111
Accumulated deficit(144)(131)(121)(114)(112)(111) 
Other undisclosed stockholders' equity attributable to parent      (109)
Total stockholders' equity:122127411(1)
TOTAL LIABILITIES AND EQUITY:1423284122

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses(13)(10)(7)(3)(2)(3)(2)
Other undisclosed operating loss      (0)
Operating loss:(13)(10)(7)(3)(2)(3)(2)
Nonoperating income (expense)01(0)0114
Investment income, nonoperating0000000
Other nonoperating income (expense)(0)0(0)(0)  (0)
Interest and debt expense(0)      
Net income (loss):(13)(10)(7)(3)(1)(2)2
Other undisclosed net income attributable to parent0      
Net income (loss) available to common stockholders, diluted:(13)(10)(7)(3)(1)(2)2

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(13)(10)(7)(3)(1)(2)2
Comprehensive income (loss), net of tax, attributable to parent:(13)(10)(7)(3)(1)(2)2

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: